MedPath

Effect of Robot Gait Training With Brain Stimulation on Gait Function in Stroke Patients

Not Applicable
Completed
Conditions
Stroke
Interventions
Device: Robot gait training
Device: Brain stimulation
Registration Number
NCT03708016
Lead Sponsor
Samsung Medical Center
Brief Summary

The purpose of this study was to investigate the effects of robot gait training with the noninvasive brain stimulation in stroke patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Age: more than 18 years
  • More than 6 months post stroke
  • Functional ambulation classification (FAC) (1~4)
Exclusion Criteria
  • Serious cardiac conditions (hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living)
  • Difficult to understand experimental tasks because of extremely severe cognitive impairment
  • History of disorders involving central nervous system
  • History of psychiatric disease
  • implanted objects that would contraindicate tDCS

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Robot gait training without brain stimulationRobot gait trainingLokomat robot training and sham tDCS on the leg motor areas
Robot gait training with brain stimulationBrain stimulationLokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
Robot gait training with brain stimulationRobot gait trainingLokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
Primary Outcome Measures
NameTimeMethod
Change in 10 meter walk test from baseline in gait speedsession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

Measure of self selected speeds by measuring the time it takes an individual to walk 10 meters. To perform the test, patient walks 10 meters (33 ft) and the time is measured when the leading foot crosses the start line and the finish line. The instructions are: "Please walk this distance at your normal pace when I say go."

Secondary Outcome Measures
NameTimeMethod
Change in Functional ambulatory category from baseline in gait functionsession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

Measure of functional ambulatory category

Change on gait function (muslce activation)session 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

All participants perform overground walking to assess the change of muscle activation using a surface EMG.

Change in Berg Balance Scale from baseline in balancesession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

Meserue of blance function

Changes in Brain activation of resting-state functional MRIsession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

Neuroplasticity measure

Change on gait function (kinematic)session 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

All participants perform overground walking to assess the change of kinematic using a motion analysis.

Change in Timed Up and Go test from baseline in balancesession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

Measure of Timued Up and Go test in balance

Change on gait function (kinetic)session 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

All participants perform overground walking to assess the change of kinetic using a force plate

Changes in motor evoked potentiasession 0 (initial visit); session 10 (at approximately 3 weeks); after 1 months from intervention termination (follow-up)

measure the motor threshold and amplitude of motor evoked potential in first dorsal interosseous muscle and TA muscle.

Trial Locations

Locations (1)

Samsung Medical Center

🇰🇷

Seoul, Gangnam-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath